Catapres-TTS patches

Transdermal (Catapres-TTS) patches that release 0.1, 0.2, 0.3 mg/24 h Guanabenz (generic, Wytensin)... 

Figure 8.7 Plasma concentration of clonidine versus time profile during and subsequent to the 7-day application of a 5 cm2 Catapres-TTS patch (Modified from Rnepp, V.M. Hadgraft, J. and Guy, R.H. (1987) CRC Critical Reviews in Therapeutic Drug Carrier Systems. 4, 13-37)...

The popular Transdermal Scop patches are widely used by travelers who experience motion sickness, and contain 1.5 mg of scopolamine solubilized to approximately 100 mg/ml in mineral oil, and deliver 1.0 mg over three days. Catapres -TTS patches contain 2.5-7.5 mg of clonidine solubilized in mineral oil, and deliver 0.1-0.3 mg/day for seven days. Vivelle-DOT patches contain 0.39-1.6 mg of estradiol solubilized in... 

Clonidine (CL) Male and female (20-39) Arm, thigh, chest Catapres-TTS patch (Boehringer Ingelheim, Germany) CL concentration in blood and urine CL concentration in plasma and urine samples chest > upper arm > thigh. Correlation found between CL release from patch and AUC. V... 

Clonidine (CL) Male (18-45) Chest, arm Catapres-TTS patch CL concentration in plasma Similar pharmacokinetic profile between sites ... 

Clonidine is also available as a transdermal patch (Catapres-TTS [transdermal therapeutic system]) that has the advantages of avoiding the need for repeated doses during the day and of reportedly lower rates of dry mouth and drowsiness (Burris, 1993). Steady-state plasma levels are reached within 2-3 days after applying the patch and clonidine concentrations reportedly diminish gradually over 2-3 days following patch removal, without rebound hypertension in adult hyper-... 

Transdermal Transderm-Scop transdermal patch system Catapres-TTS transdermal system... 

Clonidine is a potent antihypertensive agent which is well absorbed from the GI tract (95%). The dmg has a relatively long half-life (6-20 h) and a modest clearance (13 L h ). The rationale for the development of transdermal clonidine was to reduce side-effects and to improve patient compliance. Catapres-TTS, a reservoir-type patch, reached the market in 1985 in a form designed to remain in place and to deliver dmg for 7 days. Dose titration was possible via the use of systems of different active areas (3.5, 7.0, and 10.5 cm2). The control of dmg delivery over 7 days is impressive, and avoids the peaks and valleys of conventional (twice-a-day) oral administration (Figure 8.7). However, this system has not achieved as wide a success as first seemed likely because of skin sensitization. Clonidine itself, when administered transdermally on a chronic, repetitive basis, induces in a significant fraction of patients a classic immunologic skin reaction, and this has severely attenuated its use. 

Catapres TTS is the first and only transdermal patch approved by the FDA for the treatment of hypertension. Catapres TTS contains the active ingredient clondidine and was approved in 1985 [27], Catapres TTS is a seven-day patch and is a membrane-moderated transdermal patch. The patch comes in three sizes, 0.1, 0.2, and 0.3 mg/day. In addition there is also a burst dose of clonidine in the adhesive layer. The presence of the burst doses provides an immediate-release dose of clonidine which promotes rapid systemic levels of the drug. 

Clonidine patch (Catapres-TTS) 0.1-0.3 1 weekly hypertension most effective if used with a... 

---